Goldman Sachs Conviction Buy List
Goldman's Sachs' (NYSE: GS) Conviction Buy List is a listing of stocks the investment bank's research team expects to outperform.
Goldman's Sachs' regional Conviction Buy and Sell lists represent investment recommendations focused on either the size of the potential return or the likelihood of the realization of the return. (from goldmansachs.com)
SI Note: This page will track StreetInsider.com reports that mention the Goldman Sachs Conviction Buy List. It is not a complete representation of the firm's list.
To get real time e-mail alerts on Conviction Buy List news sign-up here.
UPGRADES:
Stifel Nicolaus and Baird upgrade Xyratex (Nasdaq: XRTX) to Buy and Outperform, respectively.
Goldman Sachs upgraded Deere & Co. (NYSE: DE) from Sell to Neutral, maintaining their $42 price target. The firm is citing an improved risk/reward.
JPMorgan upgrades J.C. Penney (NYSE: JCP) from Neutral ...
StreetInsider.com Pre-Open Movers:
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) 75% LOWER; announced that its Phase 3 clinical trial evaluating the Company's exclusively-licensed technology from the Mayo Clinic consisting of an intranasal antifungal lavage, SinuNase (topical amphotericin B 0.01% suspension) achieved, as anticipated, superior resolution of the cardinal symptoms of chronic sinusitis (CS), as compared to placebo control arm, however, the analysis of the unblinded primary endpoint data did not show the required level of statistical significance when comparing the SinuNase arm to the control arm.
SiRF Technology Holdings, Inc. (Nasdaq: SIRF) 21% LOWER; sees first fiscal quarter revenue of $60M to $62M revenue, compared to the prior expected range of $71M to $77M.
MGIC Investment Corporation (NYSE: MTG) 11% LOWER; agreed to sell ...
